Caught in a Covid-19 mael­strom, Eli Lil­ly locks down clin­i­cal tri­als as multi­bil­lion-dol­lar R&D ops de­rail

The Covid-19 pan­dem­ic has de­railed Eli Lil­ly’s $6 bil­lion R&D op­er­a­tions.

The phar­ma gi­ant re­port­ed Mon­day morn­ing that it has de­cid­ed to hit the brakes on most new study starts and pause en­roll­ment for most on­go­ing stud­ies. Lil­ly adds that it is con­tin­u­ing dos­ing for on­go­ing stud­ies, “but with study-by-study con­sid­er­a­tion.”

The pan­dem­ic has se­vere­ly dis­rupt­ed health­care sys­tems around the globe, says Lil­ly, mak­ing it dif­fi­cult or im­pos­si­ble to con­duct stud­ies at many re­search sites. And there’s no time­line for when it ex­pects to get back on track.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.